New progress in research on drug treatment of chronic kidney disease-mineral and bone disorder

doi:10.3877/cma.j.issn.2095-3216.2025.01.007

Abstract

Abstract:

Chronic kidney disease-mineral and bone disorder （CKD-MBD） is one of the most common and important complications of chronic kidney disease.With the progression of renal failure， the patients' calcium and phosphorus regulation becomes imbalanced.The patients may experience vitamin D deficiency， hyperphosphatemia， hypocalcemia， secondary hyperparathyroidism， and calcification of blood vessels and soft tissues.These conditions increase the risk of fractures and cardiovascular events， reduce quality of life， and increase the risk of death.Active treatment of secondary hyperparathyroidism， prevention and treatment of osteoporosis and vascular calcification， and control of blood phosphorus are important measures in the treatment of CKD-MBD.This article reviewed the new progress in research on the drug treatment of CKD-MBD.

Key words: Chronic kidney disease-mineral and bone disorder, Secondary hyperparathyroidism, Drug treatment

Yongwu1 Yu, Min Xiong, Ling Zhang. New progress in research on drug treatment of chronic kidney disease-mineral and bone disorder[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2025, 14(01): 44-47.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2025.01.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2025/V14/I01/44

References 22

［1］	刘志红，李贵森.中国慢性肾脏病矿物质和骨异常诊治指南［M］.北京：人民卫生出版社， 2019.
［2］	Liu ZH， Yu XQ， Yang JW， et al.Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis：baseline results from a prospective cohort study ［J］.Curr Med Res Opin， 2018， 34（8）： 1491-1500.
［3］	余永武，周加军，张凌.《中国慢性肾脏病矿物质和骨异常诊治指南》的解读与思考［J/OL］.中华肾病研究电子杂志，2020， 9（1）： 17-21.
［4］	Wen T， Wang Z， Chen X， et al.Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor［J］.Sci Adv， 2021， 7（23）： eabg1483.
［5］	Palmer SC， Mavridis D， Johnson DW， et al.Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults： a systematic review and network meta-analysis ［J］.Am J Kidney Dis， 2020， 76（3）： 321-330.
［6］	Shigematsu T， Koiwa F， Isaka Y， et al.Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism： a randomized placebo-controlled trial ［J］.Clin J Am Soc Nephrol， 2023， 18（10）： 1300-1309.
［7］	肖伍豪，刘抗寒.晚期慢性肾脏病患者骨质疏松症的治疗研究进展［J/OL］.中华肾病研究电子杂志， 2024， 13（2）： 92-96.
［8］	Khairallah P， Cherasard J， Sung J， et al.Changes in bone quality after treatment with etelcalcetide ［J］.Clin J Am Soc Nephrol， 2023， 18（11）： 1456-1465.
［9］	Zhang H， Li G， Yu X， et al.Progression of vascular calcification and clinical outcomes in patients receiving maintenance dialysis ［J］.JAMA Netw Open， 2023， 6（5）：e2310909.
［10］	Bressendorff I， Hansen D， Schou M， et al.The effect of magnesium supplementation on vascular calcification in CKD： a randomized clinical trial （MAGiCAL-CKD）［J］.J Am Soc Nephrol， 2023， 34（5）： 886-894.
［11］	Lu J， Li H， Wang S.The kidney reabsorption-related magnesium depletion score is associated with increased likelihood of abdominal aortic calcification among us adults ［J］.Nephrol Dial Transplant， 2023， 38（6）： 1421-1429.
［12］	Silaghi CN， Ilyés T， Filip VP， et al.Vitamin K dependent proteins in kidney disease ［J］.Int J Mol Sci， 2019， 20（7）：1571.
［13］	Haroon S， Davenport A， Ling LH， et al.Randomized controlled clinical trial of the effect of treatment with vitamin K2 on vascular calcification in hemodialysis patients （Trevasc-HDK）［J］.Kidney Int Rep， 2023， 8（9）： 1741-1751.
［14］	Andrian T， Stefan A， Nistor I， et al.Vitamin K supplementation impact in dialysis patients： a systematic review and meta-analysis of randomized trials ［J］.Clin Kidney J， 2023， 16（12）： 2738-2749.
［15］	Liu J， Zuo L， Walpen S， et al.Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia： a randomised， openlabel， multicentre， 12-week phase III study ［J］.Nephron，2023， 148（1）： 22-33.
［16］	Coyne DW， Ficociello LH， Parameswaran V， et al.Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis： a retrospective analysis of pharmacy data ［J］.Clin Nephrol， 2017， 88（2）： 59-67.
［17］	Vervloet MG， Boletis IN， de Francisco ALM， et al.Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients： a prospective observational study ［J］.Clin Kidney J， 2021， 14 （7）： 1770-1779.
［18］	Greenbaum LA， Jeck N， Klaus G， et al.Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease ［J］.Pediatr Nephrol， 2021， 36： 1233-1244.
［19］	Floege J， Covic AC， Ketteler M， et al.Long-term effects of the iron-based phosphate binder， sucroferric oxyhydroxide in dialysis patients ［J］.Nephrol Dial Transplant， 2015， 30（6）： 1037-1046.
［20］	Vervloet MG， Boletis IN， de Francisco ALM， et al.Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients： a prospective observational study ［J］.Clin Kidney J， 2021， 14（7）： 1770-1779.
［21］	Coyne DW， Ficociello LH， Parameswaran V， et al.Sucroferric oxyhydroxide in maintenance hemodialysis： a retrospective，comparative cohort study ［J］.Kidney Med， 2020， 2（3）： 307-316.
［22］	张凌，冨永芳博.慢性肾脏病甲状旁腺功能亢进［M］.北京：科学出版社， 2024 年.

[1]	Jiehua Zhu, Jialing Huang, Jianglin Wang, Yingzhong He, Wensheng Du, Jiang Huang. Drug reactivity and mutations of S gene from different genotypes of hepatitis B virus [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(04): 402-408.
[2]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[3]	Wen Liu, Dan Luo, Xiaoyu Dai, Jianbo Xianyu, Yingjuan Yu, Chunlin Zhong, Dong Wang. Progress in the research on the treatment of secondary hyperparathyroidism [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 281-284.
[4]	Dan Li, Kun Xie, Qianqian Chen, Changhua Liu. Prevention and treatment of postoperative recurrence of secondary hyperparathyroidism [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(03): 166-169.
[5]	Weisheng Chen, Mengjing Wang, Minmin Zhang. The impact of CKD-MBD on cardiovascular disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 38-42.
[6]	Yongwu Yu, JiaJun Zhou, Ling Zhang. Interpretation and thinking of the "China guidelines for diagnosis and treatment of chronic kidney disease-mineral and bone disorder" [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 17-21.
[7]	Meng Wang, Limin Wei, Hua Liu, Kehui Shi, Hongli Jiang. Therapeutic evaluation of total parathyroidectomy with autotransplantation in the treatment of secondary hyperparathyroidism [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(04): 170-175.
[8]	Dongsheng Pan, Guobiao Liang. Latest developments and future trends in the treatment of traumatic brain injury [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2024, 10(04): 193-197.
[9]	Changtong Tang, Yongnan Wang, Shiquan Wang. Analysis of drug treatment efficacy in patients with post-traumatic sympathetic hyperactivity following cranial trauma [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2024, 10(04): 233-237.
[10]	Wenyuan Liu, Xiang Wang, Hanhui Zhao, Yu Qin, Lei Dong. Changes of left ventricular function after parathyroidectomy in patients of maintenance hemodialysis with secondary hyperparathyroidism [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(02): 57-60.
[11]	Jiajun Zhou, Yongwu Yu, Han Zhou, Ling Zhang. Impact of parathyroidectomy on bone mineral density and bone metabolism in patients with secondary hyperparathyroidism [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 706-710.
[12]	Jun Dai, Shuo Li, Ying Cao, Shoufeng Wang, Hongmao Song, Jingjing Cai, Min Shao, Li Chen, Lei Cheng, De Huai. Efficacy of modified highly selective pterygoid canal nerve block by low temperature radiofrequency ablation under nasal endoscopy in patients with moderate to severe chronic rhinitis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 689-693.
[13]	Jiajun Zhou, Yongwu Yu, Han Zhou, Ling Zhang. Detection rate and distribution characteristics of ectopic parathyroid glands in 358 patients with secondary hyperparathyroidism [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 381-385.
[14]	Ping Li, Daoliang Xu, Changhua Liu. Effect of ⁹⁹Tc^m-MIBI in intraoperative localization during parathyroidectomy [J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(06): 429-434.
[15]	Hong Zhou, Weixia Yang. Clinical characteristics of bilateral medial medullary infarction in progression [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(01): 21-27.

Please choose a citation manager

Content to export